Abstract 11470: Functional Validation of the Novel Role of SMARCB1 in Myocardial Fibrosis

Min WangMahsima ShabaniDuan LiuJyotan SahniHazley J PyfferoenJoao A Ac LimaNaveen L PereiraMayo Clicnic,Rochester,MNBaltimore,MDDept of Molecular Pharmacology and Experimental Therapeutics,Mayo Clicnic,Rochester,MNJOHNS HOPKINS UNIVERSITY,Baltimore,MDMayo Clinic,Rochester,MN
DOI: https://doi.org/10.1161/circ.146.suppl_1.11470
IF: 37.8
2022-11-01
Circulation
Abstract:Circulation, Volume 146, Issue Suppl_1, Page A11470-A11470, November 8, 2022. Introduction:It has been previously demonstrated that cardiomyopathy predisposing common genetic variation inSMARCB1is associated with interstitial myocardial fibrosis (MF) as determined by cardiac MRI (CMR) linking the development of cardiomyopathy with MF.SMARCB1is known to be a tumor suppressor, but it's role in the pathophysiology of MF and fibroblast physiology has not been functionally validated.Hypothesis:SMARCB1plays an important role in regulating human cardiac fibroblast (HCF) differentiation/activation and collagen deposition, which are the critical steps in the development of MF.Methods:Cultured HCFs were treated with TGF-β1 (10ng/ml) for 48hrs to transdifferentiate into myofibroblasts, which are characterized by increased expression of α-smooth muscle actin (α-SMA, ACTA2) and collagen I (COL1A1). HCFs were transfected by siRNA using LipofectamineTM RNAiMAX Transfection Reagent to knock-down (KD) the expression ofSMARCB1. Total RNA and protein were extracted from cell lysate followed by qPCR and Western blot (WB) to quantify the expression level of SMARCB1, ACTA2 and COL1A1. Triplicate experiments were performed using biologically independent samples. For statistical analysis, a paired two-tail t-test was used.Results:HCFs treatment with TGF-β1, resulted in a significant decrease in expression ofSMARCB1(p=0.031) with accompanying significant increase in expression of ACTA2 (p=0.025) and COL1A1 (p=0.0015) as compared to control by qPCR and WB.SMARCB1KD resulted in a further significant increase in expression of ACTA2 (p=0.018) and COL1A1 (p=0.028) as compared to non-target siRNA control group at both the transcript and protein level.Conclusion:We demonstrate for the first time that a gene associated with the development of cardiomyopathySMARCB1mediates TGF-β1 induced cardiac fibrosis. These findings suggestSMARCB1as a potential therapeutic target to attenuate MF in cardiomyopathy.
cardiac & cardiovascular systems,peripheral vascular disease
What problem does this paper attempt to address?